非选择性β受体阻滞剂降低病因治疗后持续存在门脉高压的肝硬化患者首次失代偿风险
该研究纳入病因治疗后2年仍有临床显著门脉高压证据的代偿期肝硬化患者406例,比较使用与未使用非选择性β受体阻滞剂(NSBBs)者首次失代偿的发生率。平均随访32个月,NSBBs组失代偿率16% vs 未使用组44%(P < .0001),Cox回归显示NSBBs使用具保护作用(HR 0.32,95%CI 0.20-0.49,P < .0001)。
要点
- 病因治疗后持续临床显著门脉高压的肝硬化患者中,NSBBs组首次失代偿率16% vs 未使用组44%(P < .0001)。
- NSBBs的保护作用在小食管胃静脉曲张、仅有自发性门体侧支及不同病因亚组中均维持。
- NSBBs使用降低细菌感染率(HR 0.36,95%CI 0.22-0.58,P < .0001)。
核心结论
- NSBBs降低病因治疗后持续存在临床显著门脉高压的肝硬化患者首次失代偿风险。
研究设计与样本
- 研究纳入病因治疗后2年仍有临床显著门脉高压证据(食管胃静脉曲张和/或自发性门体侧支)的代偿期肝硬化患者,最终队列406例,其中使用NSBBs者187例、未使用者219例。
主要发现
- 平均随访32个月,127例(31%)发生失代偿,腹水为最常见失代偿事件(77%)。
- NSBBs组失代偿率16% vs 未使用组44%(P < .0001)。
- 小食管胃静脉曲张患者中NSBBs组失代偿率17% vs 未使用组43%(P < .0001)。
- 仅有自发性门体侧支患者中NSBBs组失代偿率8% vs 未使用组43%(P = .003)。
- 丙型肝炎病毒治愈后肝硬化患者中NSBBs组失代偿率9% vs 未使用组32%(P < .0001)。
关键数值与推荐
- Cox回归显示NSBBs使用对失代偿具保护作用(HR 0.32,95%CI 0.20-0.49,P < .0001)。
- NSBBs使用显著降低细菌感染率(HR 0.36,95%CI 0.22-0.58,P < .0001)。
- 血红蛋白、Child-Pugh评分、MELD-Na、基线糖尿病及既往细菌感染为失代偿的独立预测因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Non-selective beta-blockers (NSBBs) can lower the risk of first decompensation in patients with cirrhosis and clinically significant portal hypertension (CSPH) (identified by a hepatic venous pressure gradient ≥10 mm Hg) with active etiology. Our aim was to examine the effect of NSBBs on first decompensation occurrence in patients with cirrhosis and enduring CSPH after etiological treatment. METHODS: Patients with compensated cirrhosis and clinical evidence of CSPH (gastroesophageal varices [GEVs] and/or spontaneous portosystemic collaterals [SPSSs]) after 2 years from etiological treatment. The primary endpoint was first decompensation (occurrence of variceal bleeding, ascites, or hepatic encephalopathy) in patients on NSBBs vs off NSBBs. RESULTS: The final cohort included 406 patients. Baseline characteristics of patients on NSBBs (n = 187) and off NSBBs (n = 219) were comparable, except for signs of portal hypertension that were more pronounced in the on-NSBBs group. During a mean follow-up of 32 months, 127 (31%) patients decompensated, with ascites being the most common (77%) decompensating event. Decompensation rates were lower in patients on NSBBs (16% vs 44%; P < .0001). The benefit of NSBBs on decompensation was maintained in patients with small GEVs (17% vs 43%; P < .0001), in those with spontaneous portosystemic shunt only (8% vs 43%; P = .003), and in each different etiology, including hepatitis C virus-cured cirrhosis (9% vs 32%; P < .0001). At Cox regression analysis, hemoglobin, Child-Pugh, Model for End-Stage Liver Disease-Sodium, diabetes at baseline, and previous bacterial infections were independent predictors of decompensation, while NSBBs use had a protective effect (hazard ratio, 0.32; 95% confidence interval, 0.20-0.49; P < .0001). NSBBs use significantly reduced bacterial infection rates (hazard ratio, 0.36; 95% confidence interval, 0.22-0.58; P < .0001). CONCLUSION: NSBBs decrease the risk of first decompensation in patients with cirrhosis and enduring CSPH after etiological treatment.
引用
- Turco L, Taru MG, Vitale G, et al. Beta-Blockers Lower First Decompensation in Patients With Cirrhosis and Enduring Portal Hypertension After Etiological Treatment. Clin Gastroenterol Hepatol. 2024. PMID: 39209198. doi:10.1016/j.cgh.2024.08.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。